Skip to main content
. 2021 Jun 19;43(2):199–239. doi: 10.1210/endrev/bnab019

Table 10.

Follow-up of cluster 2 mutation carriers with a history of a PCC

Follow-up of cluster 2 mutation carriers with a history of a PCC RET (high/moderate risk for PCC), NF1, TMEM127, MAX RET(low risk for PCC)
Clinical and biochemical evaluation 12 months 12 months
Imaging (abdominal/pelvic MRI) At least every 5 years optional